This page shows the latest faldaprevir news and features for those working in and with pharma, biotech and healthcare.
Novartis pulls EMA application for expanded Tasigna use. And Boehringer confirms it won't seek approval for faldaprevir as it exits hepatitis C. ... Boehringer drops faldaprevir. Meanwhile Boehringer confirmed it has withdrawn the application for its
Boehringer pulls faldaprevir and exits hepatitis C market. Unable to challenge all-oral options from Gilead and others. ... Germany's Boehringer Ingelheim is bowing out of the race to develop oral hepatitis C virus ( HCV) therapies and has discontinued
Boehringer's faldaprevir set for rapid review in Europe. More competition in emerging hepatitis C market. ... Boehringer Ingelheim's new hepatitis C virus ( HCV) therapy faldaprevir could be on the market in the EU as early as the second half of 2014,
Boehringer says faldaprevir does well in Asian hepatitis C patients. Trial success in patients from Korea, Japan and Taiwan. ... Boehringer Ingelheim's second-generation hepatitis C virus protease inhibitor faldaprevir achieved a viral cure rate of
The combination of two of Boehringer's oral hepatitis C drugs - faldaprevir and BI 207127 - plus ribavirin achieved viral cure rate of up to 85 per cent after just 28 weeks' treatment ... Faldaprevir is a once-daily protease inhibitor while BI 207127 is
Other drugs emerging in the protease inhibitor class include Boehringer Ingelheim's faldaprevir, Merck's vaniprevir, Bristol-Myers Squibb's asunaprevir and AbbVie's ABT 450, which also claim superior viral cure rates and milder side